吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床观察

Clinical observation of advanced non-small-cell lung cancer with gemcitabine combined with cisplatin

目的:总结西宁地区(海拔2260m)盐酸吉西他滨联合顺铂化疗方案治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:我科30例Ⅲ、Ⅳ期非小细胞肺癌患者,应用GP方案盐酸吉西他滨1250mg/m2(d1,8)于60min内静脉滴注,顺铂30mg/m2(d1-2)静脉滴注,21d为1周期,治疗2个周期后评价疗效。结果:CR0例,PR14例,SD8例,PD8例,总有效率(PR+CR)为46.7(14/30);不良反应为白细胞、血小板下降和恶心、呕吐,但均可耐受。结论:高海拔地区应用盐酸吉西他滨联合顺铂方案,治疗晚期非小细胞肺癌有较好的疗效,且不良反应可以耐受。

Objective：To investigate the efficacy and toxicity of gemcitabine combined with cisplatin as chemotherapy for patients with advanced non -small lung Cancer（NSCLC） in Xining China （2260m）. Methods.Thirty patients with stage Ⅲ/Ⅳ NSCLC,who were not indicated for surgical treatment, were treated with GP regimen： gemcitabine 1250mg/m2 （ d 1,8 ） plus cisplatin 30mg/m2 （ d 1,2）, every 3 weeks. Results： The overall response rate was 46.7 % （ 14/30）, The major toxicities were leucopenia, thrombocytopenia, digestive tract reactions and alopecia. Conclusion- Gemcitabine plus cisplatin regimen is an effective and well - tolerated treatment for patients with NSCLC in Xining.